|
Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. |
|
|
Honoraria - GE Healthcare; Heel |
Consulting or Advisory Role - Bionomics; GE Healthcare; GlaxoSmithKline; Syndesi Therapeutics |
Research Funding - Bayer; GlaxoSmithKline; Johnson & Johnson; Lundbeck; Takeda; Unilever |
|
|
Research Funding - Health Clinics Limited |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bayer |
Patents, Royalties, Other Intellectual Property - Patents formulations of Bayer drug substances |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
No Relationships to Disclose |